← Leaderboards
Frank H. Ebetino
Biovinc, Llc
$9,056,711
Attributed
$10,069,192
Total exposure
10
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.4M · FY2015–25$2.5M$1.9M$1.3M$625K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,069,192 · 10
By mechanism
R44$7,413,425 · 3
R42$1,500,000 · 1
R43$780,804 · 4
R41$374,963 · 2
Top collaborators
- Parish Paymon Sedghizadeh3 shared
- Kai Chen1 shared
- Ichiro Nishimura1 shared
Most similar at Biovinc, Llc
Same institution · by research overlap
- Parish Paymon Sedghizadeh$824,982
- Kai Chen$1,252,766
Others in their field
Top investigators on “Bisphosphonate”
- Myron Max Levine · University Of Maryland Baltimore$49,565,690
- Caroline M. Tanner · Parkinson'S Institute$16,300,213
- Steven R Cummings · University Of California San Francisco$16,300,213
- Kenneth J. Pienta · Johns Hopkins University$11,873,827
- Susan L Greenspan · Beth Israel Deaconess Medical Center$11,743,082
- Robert J Levy · Children'S Hosp Of Philadelphia$10,838,958
Research focus
BisphosphonateBonePharmaceutical PreparationsSiteAffinityBaseAnimal ModelIn VivoSafetyOperative Surgical ProceduresDoseLeadAffectDrug KineticsInfectionInnovationMorbidity - Disease RateAntibioticsGenerationsOsteomyelitisDesignMortalityMedicalAntibiotic Therapy
Grant awards (17)
A Novel Bone Targeted Antibiotic Therapy for the Treatment of Infected Fractures$992,575
R44 · FY2025 · AI · contact PI
A Novel Bone Targeted Antibiotic Therapy for the Treatment of Infected Fractures$978,787
R44 · FY2024 · AI · contact PI
A Novel Bone Targeted Antibiotic Therapy for the Treatment of Infected Fractures$296,779
R44 · FY2023 · AI · contact PI
Bone targeted delivery of an antimicrobial drug for osteomyelitis therapy$988,634
R44 · FY2022 · AI · contact PI
Bone targeted delivery of an antimicrobial drug for osteomyelitis therapy$975,586
R44 · FY2021 · AI · contact PI
Bone targeted delivery of an antimicrobial drug for osteomyelitis therapy$999,300
R44 · FY2020 · AI · contact PI
Bone Metastasis Specific 18F PET Imaging Probe for Breast Cancer$225,000
R41 · FY2019 · CA · contact PI
Bone targeted antimicrobials for biofilm-mediated osteolytic infection treatment$750,000
R42 · FY2018 · DE · contact PI
Competitive Equilibrium-based Displacement of Bisphosphonates as Novel Therapeutic Approach for BRONJ$749,155
R44 · FY2018 · DE · contact PI
Competitive Equilibrium-based Displacement of Bisphosphonates as Novel Therapeutic Approach for BRONJ$691,832
R44 · FY2018 · DE · contact PI
Bone targeted antimicrobials for the treatment of diabetic foot related infections and osteomyelitis$225,000
R43 · FY2018 · AR · contact PI
Bone targeted antimicrobials for biofilm-mediated osteolytic infection treatment$750,000
R42 · FY2017 · DE · contact PI
Competitive Equilibrium-based Displacement of Bisphosphonates as Novel Therapeutic Approach for BRONJ$740,777
R44 · FY2017 · DE · contact PI
Bone targeted delivery of an antimicrobial drug for osteomyelitis therapy$180,807
R43 · FY2016 · AI · contact PI
Bone targeted antimicrobials for biofilm-mediated osteolytic infection treatment$149,963
R41 · FY2016 · DE · contact PI
Novel Bisphosphonate 18F-PET and PET/optical Dual Modality Probes for Rheumatoid Arthritis Imaging$224,997
R43 · FY2015 · AR · contact PI
Competitive Equilibrium-based Displacement of Bisphosphonates as Novel Therapeutic Approach for BRONJ$150,000
R43 · FY2015 · DE · contact PI